Skip to main content
    P

    Protara Therapeutics Inc (TARA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.40
    -0.08 (-3.23%)

    Market Cap: $146.56M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    -23.49%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.36
    Range$-0.38 - $-0.34
    6 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.34-6.4%
    60d ago$-0.33-10.8%
    30d ago$-0.33-9.7%
    7d ago$-0.33-9.7%
    Current$-0.36
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.35
    Range$-0.42 - $-0.27
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.35---
    Sep 26EST
    		-$-0.36---
    Jun 26
    Reported Aug 11
    		$-0.36$-0.33-9.09%Miss-2.9%
    Mar 26
    Reported May 13
    		$-0.31$-0.37+16.22%Beat-6.9%
    Dec 25
    Reported Mar 10
    		$-0.38$-0.31-21.79%Miss+11.6%
    Sep 25
    Reported Nov 10
    		$-0.31$-0.38+18.42%Beat+38.0%
    Jun 25
    Reported Aug 11
    		$-0.35$-0.41+14.63%Beat+22.2%
    Mar 25
    Reported May 8
    		$-0.29$-0.48+39.58%Beat+70.1%
    Dec 24
    Reported Mar 5
    		$-0.43$-0.56+23.89%Beat+52.2%
    Sep 24
    Reported Nov 12
    		$-0.50$-0.52+3.85%Beat+42.5%
    Jun 24
    Reported Aug 6
    		$-0.45$-0.74+39.19%Beat+55.0%
    Mar 24
    Reported May 2
    		$-0.97$-0.92-5.43%Miss-21.2%
    Dec 23
    Reported Mar 13
    		$-0.90$-0.92+2.17%Beat+41.9%
    Sep 23
    Reported Nov 3
    		$-0.87$-0.98+11.22%Beat-27.9%
    Jun 23
    Reported Aug 3
    		$-1.00$-0.94-6.38%Miss-25.0%
    Mar 23
    Reported May 4
    		$-0.80$-0.87+8.05%Beat+16.7%
    Dec 22
    Reported Mar 8
    		$-1.55$-0.75-106.67%Miss-70.3%
    Sep 22
    Reported Nov 3
    		$-0.68$-0.70+2.86%Beat+29.2%
    Jun 22
    Reported Aug 9
    		$-0.80$-0.78-2.56%Miss+29.8%
    Mar 22
    Reported May 5
    		$-0.96$-0.77-24.68%Miss+20.0%
    Dec 21
    Reported Mar 9
    		$-0.91$-0.94+3.19%Beat-106.8%
    Sep 21
    Reported Nov 4
    		$-0.96$-0.96+0.00%Beat+23.8%
    Jun 21
    Reported Aug 5
    		$-1.14$-0.96-18.75%Miss+6.6%
    Mar 21
    Reported May 6
    		$-1.20$-0.63-90.48%Miss+33.7%
    Dec 20
    Reported Mar 11
    		$-0.44$-0.54+18.52%Beat+82.7%
    Sep 20
    Reported Nov 12
    		$-1.26$-0.62-103.23%Miss+60.6%
    Jun 20
    Reported Jul 31
    		$-1.22$-0.83-46.99%Miss+88.7%
    Mar 20
    Reported May 13
    		$-1.81$-0.41-341.46%Miss+86.7%
    Dec 19
    Reported Mar 20
    		$-2.55$-0.71-259.15%Miss+76.4%
    Sep 19
    Reported Oct 31
    		$-3.20$-3.60+11.11%Beat+68.0%
    Jun 19
    Reported Aug 7
    		$-10.80$-6.80-58.82%Miss+3.6%
    Mar 19
    Reported May 8
    		$-13.60$-9.00-51.11%Miss+0.0%
    Dec 18
    Reported Mar 13
    		$-10.80$-10.20-5.88%Miss+12.9%
    Sep 18
    Reported Nov 7
    		$-10.00$-12.00+16.67%Beat+64.3%
    Jun 18
    Reported Aug 7
    		$-11.20$-14.20+21.13%Beat+15.2%
    Mar 18
    Reported May 9
    		$-13.60$-13.84+1.73%Beat+12.8%
    Dec 17
    Reported Mar 14
    		$-12.40$-16.80+26.19%Beat+26.2%
    Sep 17
    Reported Nov 7
    		$-28.00$-15.53-80.30%Miss-
    Jun 17
    Reported Aug 7
    		$-13.20$-17.20+23.26%Beat-
    Mar 17
    Reported May 10
    		$-15.60$-16.70+6.59%Beat-
    Dec 16
    Reported Mar 16
    		$-16.80$-18.30+8.20%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.76EV/EBITDAN/A
    Price/FCF-2.20xFCF Yield-45.41%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-45.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio10.97xQuick Ratio10.97x
    Trading Statistics
    Beta1.47Avg Volume1.71M
    52-Week High$7.8252-Week Low$2.47

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.62
    SMA 20$2.97
    SMA 50$3.53
    SMA 200$4.72
    EMA 10$2.67
    EMA 20$2.92
    EMA 50$3.38
    EMA 200$4.23

    MACD

    Line: -0.32Signal: -0.29Hist: -0.02

    ADX

    ADX: 42.5+DI: 8.1-DI: 34.2

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down100.0
    PSAR$2.82

    Bollinger Bands

    Upper Band$3.80
    Lower Band$2.14
    %B Position5590%(Upper)
    Band Width0.16

    RSI (14-Day)

    Oversold
    22.6

    Momentum Oscillators

    Stoch %K4.7
    Stoch %D10.7
    Williams %R-97.5
    ROC (10d)-13.0%
    Momentum-0.36
    CCI (20d)-98.1
    MFI (14d)12.4

    Volatility Measures

    ATR (14d)$0.19(8.1%)
    StdDev (20d)0.41
    Hist Vol55.3%(High)

    Volume Flow

    VWAP$2.44
    OBV-39.7M
    AD Line-35.9M
    CMF (20d)-0.441

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio0.5x(Low)
    VWMA (20d)$3.03

    Pivot Points

    R3$2.79
    R2$2.73
    R1$2.60
    Pivot Point$2.54
    S1$2.41
    S2$2.35
    S3$2.22

    Advanced Oscillators

    TSI-50.03
    Ultimate Osc32.7
    KST-288.47

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$332,000$0$0$0$1.21M$0
    Cost of Revenue$0$0$93,000$0$0$0N/A$0$0$0$107,000$0
    Gross Profit$0$0$-93,000$0$0$0$166,000$0$0$0$1.10M$0
    Operating Expenses$23.32M$19.63M$19.08M$14.76M$16.59M$14.12M$14.31M$12.33M$10.66M$11.85M$11.04M$10.70M
    R&D$16.95M$13.56M$13.12M$9.59M$10.77M$9.15M$9.50M$8.07M$6.39M$7.75M$6.38M$6.22M
    SG&A$6.37M$6.07M$5.96M$5.17M$5.82M$4.98M$4.81M$4.26M$4.27M$4.10M$4.66M$4.48M
    Operating Income$-23,324,000$-19,629,000$-19,079,000$-14,760,000$-16,586,000$-14,124,000$-14,312,000$-12,330,000$-10,661,000$-11,851,000$-11,041,000$-10,700,000
    Interest Income$1.66M$1.85M$1.52M$1.50M$1.63M$1.73M$1.16M$1.11M$1.15M$756,000$820,000$840,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-21,668,000$-17,782,000$-17,307,000$-13,258,000$-14,960,000$-11,914,000$-12,769,000$-11,219,000$-9,513,000$-11,095,000$-10,221,000$-9,860,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-21,668,000$-17,782,000$-17,307,000$-13,258,000$-14,960,000$-11,914,000$-12,769,000$-11,219,000$-9,513,000$-11,095,000$-10,221,000$-9,860,000
    EBITDA$-23,252,000$-19,539,000$-19,054,000$-15,068,000$-16,854,000$-13,726,000$-14,122,000$-12,577,000$-10,585,000$-11,836,000$-11,047,000$-10,748,000
    EBIT$-23,324,000$-19,629,000$-18,830,000$-14,760,000$-16,586,000$-13,643,000$-13,925,000$-12,330,000$-10,661,000$-11,851,000$-11,041,000$-10,700,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TARA

    News

    Protara completes enrollment in Phase 2b trial for IV choline By Investing.com

    Protara Therapeutics has completed enrollment for the Phase 2b portion of its THRIVE-3 clinical trial, evaluating IV Choline Chloride for patients with intestinal failure dependent on parenteral support. The company...

    Investing.com India•10/15/26•Somewhat-Bullish

    Protara completes enrollment in Phase 2b trial for IV choline

    Protara Therapeutics Inc. (NASDAQ:TARA) has completed enrollment for the Phase 2b portion of its THRIVE-3 clinical trial...

    Investing.com•10/15/26•Bullish

    About 80% of U.S. adults who rely on nutrition through a vein lack choline. Protara enrolled 24 in its study.

    Protara Therapeutics has completed enrollment for the Phase 2b open-label dose confirmation portion of its THRIVE-3 registrational trial for IV Choline Chloride. This phase involves 24 patients and aims to evaluate...

    Stock Titan•10/15/26•Bullish

    Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

    Protara Therapeutics has completed enrollment for the Phase 2b open-label dose confirmation phase of its THRIVE-3 clinical trial...

    Yahoo Finance Singapore•10/15/26•Bullish

    Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

    Protara Therapeutics announced the completion of enrollment for the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This trial aims to evaluate the efficacy and safety of IV...

    Yahoo Finance•10/15/26•Bullish

    TARA Valuation and Fair Value

    P/E
    -1.8x
    P/FCF
    -2.2x
    P/B
    0.9x
    See GNG's fair value

    TARA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -45.8%
    FCF yield
    -45.4%

    TARA Competitors

    CompanyTicker
    Organogenesis Holdings IncORGO
    Nkarta IncNKTX
    Sound Point Meridian Capital, Inc.SPMC
    Quanterix CorpQTRX
    Mersana Therapeutics IncMRSN
    Neuronetics IncSTIM
    JIN MEDICAL INTERNATIONAL LTD. Ordinary SharesZJYL
    Cardiol Therapeutics Inc Class ACRDL

    Sector: Healthcare

    TARA Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    2
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    TARA Bull Case vs Bear Case

    Bull case

    • TARA beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of TARA's analyst ratings are Buy or Strong Buy.

    TARA Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    10.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.36
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 3 down

    Frequently Asked Questions About TARA

    Does TARA pay dividends?

    Protara Therapeutics Inc (TARA) does not currently pay a regular dividend.

    What is TARA's market cap?

    Protara Therapeutics Inc (TARA) has a market capitalization of $146.56M with a current stock price of $2.40.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In